Determinants of chronic renal allograft rejection in cyclosporine-treated recipients. 1996

S M Flechner, and C S Modlin, and D P Serrano, and D A Goldfarb, and D Papajcik, and B Mastroianni, and M Goormastic, and A C Novick
Department of Urology, Cleveland Clinic Foundation, Ohio 44195, USA.

We analyzed the development of chronic rejection in 511 kidney-only renal transplants in 507 patients between July 1987 and November 1994. A database was established for recipients > or = 18 years old who received cyclosporine-based immunosuppression and demonstrated graft survival for a minimum of 12 months. The 347 recipients of cadaver transplants (67.9%) and 164 recipients of live donor transplants (32.1%) were followed for 12 to 102 months (mean 51 months). Chronic rejection was diagnosed in 124 transplants (24%), with a mean time to diagnosis of 23+/-18 months (range 3-92). Risk factors were identified in a multivariate analysis using the Cox model. The impact of the timing and severity of rejection episodes was analyzed in a univariate model. The presence of chronic rejection resulted in decreased (P=0.0001) 5-year graft survival for both cadaver graft (83.7% vs. 58.2%) and live donor graft (93.2% vs. 53.1%) recipients. Significant variables for the development of chronic rejection included an acute rejection episode (P=0.0001), a black recipient (P=0.0006), donor age > or = 50 years (P=0.006), and a serum creatinine level >2.0 mg/dl by 6 months after transplantation. Severity of rejection measured by peak serum creatinine or posttreatment return to baseline was not related to chronic rejection. However, acute rejection episodes lasting for more that 5 days (P=0.03) or occurring after 6 months (P=0.001) did influence time to chronic rejection. In addition, mismatching for donor-recipient race was a significant (P=0.008) risk factor for recipients of cadaver grafts. We conclude that acute rejection is the most significant risk factor for chronic rejection, and the long-term fate of grafts may be determined as early as the first 6 months. Racial matching of donor-recipient pairs may be useful to minimize chronic rejection risk. Future advances that diminish the incidence and severity of acute rejection may have the greatest impact on long-term survival.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D006084 Graft Rejection An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient. Transplant Rejection,Rejection, Transplant,Transplantation Rejection,Graft Rejections,Rejection, Graft,Rejection, Transplantation,Rejections, Graft,Rejections, Transplant,Rejections, Transplantation,Transplant Rejections,Transplantation Rejections
D006085 Graft Survival The survival of a graft in a host, the factors responsible for the survival and the changes occurring within the graft during growth in the host. Graft Survivals,Survival, Graft,Survivals, Graft
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000208 Acute Disease Disease having a short and relatively severe course. Acute Diseases,Disease, Acute,Diseases, Acute
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012307 Risk Factors An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, based on epidemiological evidence, is known to be associated with a health-related condition considered important to prevent. Health Correlates,Risk Factor Scores,Risk Scores,Social Risk Factors,Population at Risk,Populations at Risk,Correlates, Health,Factor, Risk,Factor, Social Risk,Factors, Social Risk,Risk Factor,Risk Factor Score,Risk Factor, Social,Risk Factors, Social,Risk Score,Score, Risk,Score, Risk Factor,Social Risk Factor
D014184 Transplantation, Homologous Transplantation between individuals of the same species. Usually refers to genetically disparate individuals in contradistinction to isogeneic transplantation for genetically identical individuals. Transplantation, Allogeneic,Allogeneic Grafting,Allogeneic Transplantation,Allografting,Homografting,Homologous Transplantation,Grafting, Allogeneic
D016030 Kidney Transplantation The transference of a kidney from one human or animal to another. Grafting, Kidney,Renal Transplantation,Transplantation, Kidney,Transplantation, Renal,Kidney Grafting,Kidney Transplantations,Renal Transplantations,Transplantations, Kidney,Transplantations, Renal

Related Publications

S M Flechner, and C S Modlin, and D P Serrano, and D A Goldfarb, and D Papajcik, and B Mastroianni, and M Goormastic, and A C Novick
June 1988, Transplantation proceedings,
S M Flechner, and C S Modlin, and D P Serrano, and D A Goldfarb, and D Papajcik, and B Mastroianni, and M Goormastic, and A C Novick
February 1987, Transplantation proceedings,
S M Flechner, and C S Modlin, and D P Serrano, and D A Goldfarb, and D Papajcik, and B Mastroianni, and M Goormastic, and A C Novick
October 1988, Transplantation proceedings,
S M Flechner, and C S Modlin, and D P Serrano, and D A Goldfarb, and D Papajcik, and B Mastroianni, and M Goormastic, and A C Novick
February 1991, Transplantation,
S M Flechner, and C S Modlin, and D P Serrano, and D A Goldfarb, and D Papajcik, and B Mastroianni, and M Goormastic, and A C Novick
January 1988, American journal of clinical pathology,
S M Flechner, and C S Modlin, and D P Serrano, and D A Goldfarb, and D Papajcik, and B Mastroianni, and M Goormastic, and A C Novick
June 1987, Human immunology,
S M Flechner, and C S Modlin, and D P Serrano, and D A Goldfarb, and D Papajcik, and B Mastroianni, and M Goormastic, and A C Novick
November 1988, Transplantation,
S M Flechner, and C S Modlin, and D P Serrano, and D A Goldfarb, and D Papajcik, and B Mastroianni, and M Goormastic, and A C Novick
February 1987, Transplantation,
S M Flechner, and C S Modlin, and D P Serrano, and D A Goldfarb, and D Papajcik, and B Mastroianni, and M Goormastic, and A C Novick
December 1984, Transplantation,
S M Flechner, and C S Modlin, and D P Serrano, and D A Goldfarb, and D Papajcik, and B Mastroianni, and M Goormastic, and A C Novick
September 1995, Urology,
Copied contents to your clipboard!